Tagged spinal-muscular-atrophy
Press Release
Families of SMA and Nationwide Children's Hospital Announce Multi-Million Dollar Award from NINDS
Nationwide Children's Hospital and Families of Spinal Muscular Atrophy announce the award of a multi-million dollar cooperative agreement from the NINDS to advance a gene therapy development program for Spinal Muscular Atrophy. Read More
Press Release
Families of SMA Announces $1.4 Million Planned for Next Round of Spinal Muscular Atrophy Research Funding
Families of Spinal Muscular Atrophy (FSMA) is dedicated to creating a treatment and cure for Spinal Muscular Atrophy (SMA) by funding and advancing a comprehensive research program Read More
Press Release
Repligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA).
Repligen Corporation (NASDAQ:RGEN) today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of SMA. Read More
Press Release
Jacob Isaac Rappoport Foundation Aims for Million Dollar Milestone Supporting SMA Research
With the 9th Annual Jacob's Run, Walk & Roll Event to be held on April 1st, The Jacob Isaac Rappoport Foundation is aiming to reach the milestone of raising $1,000,000 for Spinal Muscular Atrophy (SMA) Research Read More
Press Release
Families of Spinal Muscular Atrophy Awards 7 New Basic Research Grants for $745,000.
Awards will help develop new approaches for SMA therapies. These new awards encompass $745,000 for the basic research portion of the $3 Million in new research funding that FSMA announced earlier this year. Read More
Press Release
Families of Spinal Muscular Atrophy Awards $3 Million in New SMA Research Funding
The new funding awards will be allocated into three distinct research areas: 1)Basic Research to understand the disease, 2)Drug Discovery to develop new SMA therapies, and 3)Clinical Research to provide the means to test new drugs effectively. Read More
Press Release
MDA Invests $1.4 Million to Help Advance the Families of SMA Quinazoline Drug Program for Spinal Muscular Atrophy at Repligen Corporation.
The MDA has committed to invest funds in the FSMA Quinazoline Program at Repligen Corporation to assist in advancing the program to an IND filing with the FDA. Read More
Press Release
Families of Spinal Muscular Atrophy Launches Next Phase of Drug Development Efforts for SMA
Families of SMA announces Request for Proposals (RFP) for new drug programs to develop therapies for Spinal Muscular Atrophy. FSMA is aiming to fund two new preclinical drug development programs in 2011, with more to follow. Read More
Press Release